Method of using hepatic progenitors in treating liver dysfunction

a technology of liver dysfunction and hepatic progenitors, which is applied in the direction of non-embryonic pluripotent stem cells, biocide, drug compositions, etc., can solve the problems of patient vulnerability, immunosuppressants are not always affective, and the time and effort is exhausted to genetically, and achieves the effect of low immunosuppressant levels

Inactive Publication Date: 2007-06-28
VESTA THERAPEUTICS INC
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] In one embodiment of the present invention, a method of repopulating the liver compartment of a mammal is provided, comprising (a) providing isolated hepatic progenitors and (b) administering said isolated hepatic progenitors into the liver compartment of the mammal; wherein the admi

Problems solved by technology

Indeed, among genetically non-identical patients, the host's body may reject donor tissue in a matter of hours.
To account for this potential, substantial time and effort is exhausted to genetically “match” donors with possible hosts.
Unfortunately, immunosuppressants are not a panacea.
First, immunosuppressants are not al

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of using hepatic progenitors in treating liver dysfunction
  • Method of using hepatic progenitors in treating liver dysfunction
  • Method of using hepatic progenitors in treating liver dysfunction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] The instant invention provides for methods of transplanting hepatic progenitor cells into mammals without the need of currently standard doses of immunosuppressants, if any at all. That is, in a preferred embodiment of the invention, hepatic progenitors may be introduced into an allogenic host with little to no concomitant administration of an immunosuppressants to prevent the rejection thereof.

[0018] Currently, most, if not all, partial or whole liver transplants into an allogeneic recipient requires the use of an immunosuppressant in order to prevent immune rejection (i.e., GVHD) of the transplanted tissue. While the dose and duration of immunosuppresant use varies greatly among transplants according to factors, such as tissue to, relative genetic “match”, the instant discovery and invention provides a significant reduction in the overall usage of the drugs. Common immunosuppressants include, but are not limited to consisting of prednisone (e.g., ORASONE®), azathioprine (e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

Methods of using hepatic progenitors in treating liver dysfunction are provided. More particularly, methods of using hepatic progenitor cells, including hepatic stem cells, in treating liver dysfunction in the absence of immune-suppressing amounts of an immunosuppressant.

Description

CROSS REFERENCES TO RELATED PATENT APPLICATIONS [0001] This application claims priority to U.S. Provisional Application No. 60 / 752,597, filed Dec. 22, 2005, the disclosure of which has been incorporated herein by reference in its entirety.FIELD OF THE INVENTION [0002] The present invention relates generally to the use of using hepatic progenitors in treating liver dysfunction. More particularly, the present invention relates to methods of using hepatic progenitor cells, including hepatic stem cells, in treating liver dysfunction without concomitant use of immunosuppressants. BACKGROUND OF THE INVENTION [0003] The efficacy of whole and partial liver transplants is substantially dependent on the host's immune response (e.g., Graft versus Host Disease (“GVHD”)). Indeed, among genetically non-identical patients, the host's body may reject donor tissue in a matter of hours. To account for this potential, substantial time and effort is exhausted to genetically “match” donors with possible...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/407A61K35/12C12N5/074
CPCA61K31/352A61K31/365A61K31/573A61K35/12A61K35/407A61K38/13C12N5/0672A61K2300/00A61P1/16C12N5/0602C12N5/0607
Inventor JOHNSTON, MARKLUDLOW, JOHNSHERWOOD, SONYA
Owner VESTA THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap